News | November 15, 2011

Instantaneous Wave-Free Ratio (iFR) Measures Stenosis Severity Without Adenosine

November 15, 2011 — The ADVISE clinical trial concluded that a new measure of stenosis severity — instantaneous wave-free ratio (iFR) — yielded similar results to traditional fractional flow reserve (FFR) without using adenosine to induce maximum hyperemia. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

FFR, while the leading invasive measure of stenosis severity, is only used in 6 percent or fewer of percutaneous coronary intervention (PCI) cases in the United States. One reason is the required use of the drug adenosine, which minimizes and stabilizes coronary resistance during the test but is uncomfortable for patients. FFR is also time-consuming and expensive.

In ADVISE (ADenosine Vasodilation Independent Stenosis Evaluation), 157 stenoses (131 patients) were recruited to this pilot, non–randomized, international, multi-center study. In their investigations, researchers developed a new pressure-based index that does not require adenosine.

Wave intensity analysis was used during the trial. It identified a period during the normal heart rhythm cycle where intracoronary resistance at rest is similar in variability and magnitude (CV: 0.08±0.06 and 284±147mmHg.s/m) to those during FFR (CV: 0.08±0.06 and 302±315mmHg.s/m, p=NS for both).

The resting ratio of the distal-to-proximal pressure during this period, iFR, correlated closely with FFR (r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under curve of 93 percent, at FFR<0.8), specificity, sensitivity, and negative and positive predictive values of 91 percent, 85 percent, 85 percent and 91 percent, respectively.

“The results of the ADVISE trial indicate that intracoronary resistance is naturally constant and minimized during the wave-free period. The instantaneous wave-free ratio (iFR) calculated over this period produces a drug-free index of stenosis severity that is comparable to FFR,” said principal investigator Justin Davies, MBBS, MRCP, Ph.D. Davies is a clinical academic and interventional cardiologist at the National Heart and Lung Institute at Imperial College London.

“The clinical implications of the trial are that significant barriers to a physiological assessment of stenoses have been removed, and the new technique can potentially improve workflow in the cath lab, leading to a better patient experience and increased adoption,” said Davies.

The ADVISE trial was funded by the National Institute for Health Research, Biomedical Research Council and the Coronary Flow Trust and supported by Volcano Corp. Davies holds licensed patents pertaining to this technology and has acted as a consultant for Volcano.

For more information: www.crf.org

 

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init